Lexaria Announces 2nd Tranche Closing of Non-Brokered Private Placement
Kelowna, British Columbia– November 29, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has closed the…
Lexaria’s Technology Now Works in Less Than 10 Minutes
Kelowna, British Columbia– November 21, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has developed additional…
Lexaria Announces Closing of Non-Brokered Private Placement
Kelowna, British Columbia– November 14, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has closed the…
Lexaria Awards Options
Kelowna, British Columbia– November 5, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has issued certain…
Lexaria Bioscience Appoints Gregg Smith as Senior Advisor Evolution VC Partners participates in equity financing
Kelowna, British Columbia– November 5, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is very pleased to announce…
Lexaria Corporate Financing and Update
Kelowna, British Columbia– October 30, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it is arranging a non-brokered…
Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format
Kelowna, British Columbia– October 24, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is very pleased to report…
Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria
Kelowna, British Columbia– October 8, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this…
Peer Reviewed Clinical Journal Publishes Lexaria Bioscience’s Human CBD Study Results
Kelowna, British Columbia– September 17, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
Kelowna, British Columbia– August 27, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that…